CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study

被引:265
作者
Mussini, Cristina [1 ]
Lorenzini, Patrizia [2 ]
Cozzi-Lepri, Alessandro [3 ]
Lapadula, Giuseppe [4 ]
Marchetti, Giulia [5 ]
Nicastri, Emanuele [2 ]
Cingolani, Antonella [6 ]
Lichtner, Miriam [7 ]
Antinori, Andrea [2 ]
Gori, Andrea [4 ]
Monforte, Antonella d'Arminio [5 ]
机构
[1] Univ Modena & Reggio Emilia, Clin Infect Dis, Modena, Italy
[2] Natl Inst Infect Dis, Rome, Italy
[3] UCL, Hlth Div Populat Hlth, Dept Infect & Populat, London, England
[4] Univ Milano Bicocca, San Gerardo Hosp, Dept Infect Dis, Monza, Italy
[5] Univ Milan, San Paolo Hosp, Dept Hlth Sci, Clin Infect Dis, Milan, Italy
[6] Univ Cattolica Sacro Cuore, Clin Infect Dis, Rome, Italy
[7] Univ Roma La Sapienza, Dept Publ Hlth & Infect Dis, Polo Pontino, Italy
关键词
T-CELL-ACTIVATION; CLINICAL PROGRESSION; IMMUNE PARAMETERS; INFECTED PATIENTS; OLD POPULATION; SWEDISH PEOPLE; MORTALITY; INFLAMMATION; RISK; COAGULATION;
D O I
10.1016/S2352-3018(15)00006-5
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background In patients with HIV, immune reconstitution after antiretroviral therapy (ART) is often incomplete. We assessed the probability of patients reaching a CD4/CD8 ratio of 1 or more after the start of ART and its association with the onset of non-AIDS-defi ning events and death. Methods We did an analysis of the ICONA cohort, which recruited treatment-naive patients with HIV in Italy. We included participants in the cohort who started ART, reached an undetectable viral load (<= 80 copies per mL), and had a CD4/CD8 ratio of less than 0.8 at the time of an undetectable viral load. We defined ratio normalisation in patients as two consecutive values of 1 or more. We used Kaplan-Meier curves to estimate the cumulative probability of ratio normalisation. We then used Poisson regression models to identify factors independently associated with normalisation and with progression to non-AIDS-defi ning events or death. Findings We included 3236 participants, enrolled between Jan 22, 1997, and Feb 25, 2013. At the start of ART, median CD4/CD8 ratio in our population was 0.39 (IQR 0.26-0.55). 458 (14%) patients reached a CD4/CD8 ratio of 1 or more; the estimated probability of normalisation was 4.4% (95% CI 3.7-5.2) by 1 year from baseline, 11.5% (10.2-13.0) by 2 years, and 29.4% (26.7-32.4) by 5 years. Factors associated with normalisation were high pre-ART CD4 cell counts, a high CD4/CD8 ratio at baseline, and negative cytomegalovirus serological findings. The incidence rate of non-AIDS-defi ning events for patients with a CD4/CD8 ratio of less than 0.30 (4.2 per 100 patient-years, 95% CI 3.4-5.3) was double that for those with a ratio of 0.30-0.45 (2.3, 2.1-2.5) or more than 0.45 (2.2, 1.7-2.9). A ratio of less than 0.30 was independently associated with an increased risk of non-AIDS-defi ning events or death compared with one of more than 0.45. Interpretation Few patients had normalised CD4/CD8 ratios, even though they had viral suppression. Low ratios were associated with increased risk of serious events and deaths. The CD4/CD8 ratio could be used by clinicians to identity patients at risk of non-AIDS-related events.
引用
收藏
页码:E98 / E106
页数:9
相关论文
共 30 条
[1]   Changes in the risk of death after HIV seroconversion compared with mortality in the general population [J].
Bhaskaran, Krishnan ;
Hamouda, Osamah ;
Sannes, Mette ;
Boufassa, Faroudy ;
Johnson, Anne M. ;
Lambert, Paul C. ;
Porter, Kholoud .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2008, 300 (01) :51-59
[2]  
Burnham K.P., 1998, MODEL SELECTION INFE
[3]   HIV Infection, Inflammation, Immunosenescence, and Aging [J].
Deeks, Steven G. .
ANNUAL REVIEW OF MEDICINE, VOL 62, 2011, 2011, 62 :141-155
[4]   IMMUNE PARAMETERS IN A LONGITUDINAL-STUDY OF A VERY OLD POPULATION OF SWEDISH PEOPLE - A COMPARISON BETWEEN SURVIVORS AND NONSURVIVORS [J].
FERGUSON, FG ;
WIKBY, A ;
MAXSON, P ;
OLSSON, J ;
JOHANSSON, B .
JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES, 1995, 50 (06) :B378-B382
[5]   Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV [J].
Gallant, JE ;
DeJesus, E ;
Arribas, JR ;
Pozniak, AL ;
Gazzard, B ;
Campo, RE ;
Lu, B ;
McColl, D ;
Chuck, S ;
Enejosa, J ;
Toole, JJ ;
Cheng, AK .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (03) :251-260
[6]  
Guiguet M, 2009, ANTIVIR THER, V14, P451
[7]   Longitudinal studies of clonally expanded CD8 T cells reveal a repertoire shrinkage predicting mortality and an increased number of dysfunctional cytomegalovirus-specific T cells in the very elderly [J].
Hadrup, SR ;
Strindhall, J ;
Kollgaard, T ;
Seremet, T ;
Johansson, B ;
Pawelec, G ;
Straten, PT ;
Wikby, A .
JOURNAL OF IMMUNOLOGY, 2006, 176 (04) :2645-2653
[8]   Does an Index Composed of Clinical Data Reflect Effects of Inflammation, Coagulation, and Monocyte Activation on Mortality Among Those Aging With HIV? [J].
Justice, Amy C. ;
Freiberg, Matthew S. ;
Tracy, Russ ;
Kuller, Lew ;
Tate, Janet P. ;
Goetz, Matthew Bidwell ;
Fiellin, David A. ;
Vanasse, Gary J. ;
Butt, Adeel A. ;
Rodriguez-Barradas, Maria C. ;
Gibert, Cynthia ;
Oursler, Kris Ann ;
Deeks, Steven G. ;
Bryant, Kendall .
CLINICAL INFECTIOUS DISEASES, 2012, 54 (07) :984-994
[9]   Inflammatory and Coagulation Biomarkers and Mortality in Patients with HIV Infection [J].
Kuller, Lewis H. ;
Tracy, Russell ;
Belloso, Waldo ;
De Wit, Stephane ;
Drummond, Fraser ;
Lane, H. Clifford ;
Ledergerber, Bruno ;
Lundgren, Jens ;
Neuhaus, Jacqueline ;
Nixon, Daniel ;
Paton, Nicholas I. ;
Neaton, James D. .
PLOS MEDICINE, 2008, 5 (10) :1496-1508
[10]   Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment [J].
Lapadula, Giuseppe ;
Cozzi-Lepri, Alessandro ;
Marchetti, Giulia ;
Antinori, Andrea ;
Chiodera, Alessandro ;
Nicastri, Emanuele ;
Parruti, Giustino ;
Galli, Massimo ;
Gori, Andrea ;
Monforte, Antonella d'Arminio .
AIDS, 2013, 27 (05) :769-779